Pembrolizumab-Ipilimumab Combo Boosts Toxicity, Not Survival in NSCLCFebruary 7th 2021
Pembrolizumab (Keytruda) combined with ipilimumab (Yervoy) did not improve survival and had higher rates of toxicity compared with pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) who had a PD-L1 tumor proportion score (TPS) of 50% or greater, and did not harbor EGFR or ALK aberrations.
Immunotherapy May Highlight Neoadjuvant Treatment's Use in Lung CancerJanuary 25th 2021
The radiographic and pathologic responses that have been seen with checkpoint inhibitors in lung cancer bodes well for the use of neoadjuvant therapy. However, the relationship between response and long-term outcomes, specifically with regard to overall survival, will have to be teased out before they become standard practice, explained David Spigel, MD.
Nivolumab Plus Cabozantinib Gets Priority Review for Advanced RCC TreatmentOctober 20th 2020
The FDA has granted a priority review designation to a supplemental biologics license application and supplemental new drug application for nivolumab (Opdivo) plus cabozantinib (Cabometyx) for the treatment of patients with advanced renal cell carcinoma.
Immunotherapy Combos in Advanced Nonsquamous NSCLC: What Does the Data Say?September 29th 2020
The paradigm of advanced nonsquamous non–small cell lung cancer (NSCLC) is now one that necessitates discussions regarding the use of combination chemoimmunotherapy, combination immunotherapy, and single-agent immunotherapy, explained Jonathan Dowell, MD.
Investigational CAR T-Cell Product Plus Immunotherapy Is Active in DLBCLSeptember 26th 2020
The investigational CAR T-cell product AUTO3 in combination with pembrolizumab (Keytruda) was found to have a tolerable safety profile and elicit durable complete responses (CRs) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to results of the single-arm, phase 1/2 ALEXANDER study that were presented during the virtual 2020 ESMO Congress.
Novel Molecule Enhances Immunotherapy Response in CRC, According to Early DataSeptember 19th 2020
The advent of immunotherapy has revolutionized multiple areas of cancer treatment, said Timothy Cragin Wang, MD, who added that the transformative potential of the modality has been mild at best in the field of colorectal cancer (CRC).
Pursuing Immunotherapy for Sarcoma TreatmentAugust 25th 2020
Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with regard to determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.
Immunotherapy Is Promising for Cisplatin-Ineligible Metastatic Urothelial CancerAugust 18th 2020
Several trials in the field of first-line metastatic urothelial cancer are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab (Bavencio). However, no phase 3 trials have shown that first-line pembrolizumab (Keytruda) is better than gemcitabine and platinum-based therapy followed by avelumab as maintenance, according to Guru P. Sonpavde, MD.
Immunotherapy/Chemotherapy Regimen Improves Lung Cancer Outcomes, Regardless of Biomarker StatusJune 23rd 2020
The combination of atezolizumab (Tecentriq) plus carboplatin/etoposide continued to demonstrate an improvement in overall survival (OS) versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), regardless of PD-L1 and blood tumor mutational burden (bTMB) status.
Upfront 4-Drug Regimen Is Tolerable in Lung Cancer TreatmentJune 11th 2020
The 4-drug combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel (ABCP) improved survival while maintaining good health-related quality of life (QOL) in patients with nonsquamous non–small cell lung cancer .
When to Stop Immunotherapy in Metastatic Lung Cancer: Expert Weighs InMay 27th 2020
Immunotherapy should be continued for up to 2 years in patients with metastatic lung cancer who are responding to the treatment, unless they experience disease progression or excessive toxicity, according to Gilberto de Lima Lopes, MD.
Expert Talks Immunotherapy for TNBC TreatmentMay 16th 2020
The addition of immunotherapy to the triple-negative breast cancer (TNBC) armamentarium has led to a paradigm shift and sparked an abundance of research with immuno-oncology (IO) drugs in new combinations and settings, explained Hope S. Rugo, MD.
FDA Approves Durvalumab Plus Standard of Care for SCLCMarch 30th 2020
The FDA approved durvalumab (Imfinzi) plus standard-of-care (SoC) chemotherapies etoposide with either carboplatin or cisplatin (platinum-etoposide) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Immunotherapy in SCLC: Results Are Promising, But Biomarkers Are NeededMarch 16th 2020
After nearly 4 decades of stagnation, the advent of immunotherapy has transformed the frontline treatment paradigm for patients with extensive-stage small cell lung cancer (ES-SCLC). However, biomarkers are needed to better inform which patients are most likely to respond to checkpoint inhibitors, said Jason Niu, MD, PhD.
Immunotherapy Plus Chemo Improves Metastatic TNBC OutcomesFebruary 14th 2020
The frontline combination of pembrolizumab (Keytruda) and chemotherapy significantly improved progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 (combined positive score [CPS] ≥10), meeting one of the dual primary endpoints of the phase III KEYNOTE-355 trial.